CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 24 enrolled
Drug / intervention
fluticasone furoatedrug
Likely dose
fluticasone furoate 55 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00603044
NCT00603044Phase 4Completed
CompareCT.gov

Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome

University of Chicago·interventional·Posted Jan 28, 2008·Updated May 4, 2015

In Brief

A Phase 4 clinical trial evaluating fluticasone furoate for Childhood Obstructive Sleep Apnea Syndrome (OSAS). Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this research is to find out how a nasal spray (fluticasone furoate), sometimes given to children with obstructive sleep apnea syndrome (OSAS), works on certain cells within a child's adenoids. We hypothesize that intranasal steroids lead to an upregulation of T regulatory cells in the adenoid tissues of children with OSAS. This will result in a local reduction in inflammation and edema explaining the improvement in OSAS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChildhood Obstructive Sleep Apnea Syndrome (OSAS)
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 28, 2008
Enrollment StartJan 1, 2008
Primary CompletionJan 1, 2009
Study CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.4 years ago

Interventions

fluticasone furoatedrug

treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy